Trial reportAndrology2013
Characteristics associated with suppression of spermatogenesis in a male hormonal contraceptive trial using testosterone and Nestorone(®) gels.
Trial report in Andrology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 31 citations in OpenAlex.
- Daily Oral Administration of the Novel Androgen 11β-MNTDC Markedly Suppresses Serum Gonadotropins in Healthy Men.The Journal of clinical endocrinology and metabolism · 2020Trial
- Combined nestorone-testosterone gel suppresses serum gonadotropins to concentrations associated with effective hormonal contraception in men.Andrology · 2019Trial
- Acceptability of a transdermal gel-based male hormonal contraceptive in a randomized controlled trial.Contraception · 2014Trial
- Trial
- Development of a transdermal gel for reversible male contraception.Contraception · 2025Review
- Synthetic androgens for male contraception.Contraception · 2025Review
- Male Hormonal Contraception-Current Stage of Knowledge.Journal of clinical medicine · 2025Review
- Male contraception: narrative review of ongoing research.Basic and clinical andrology · 2023Review
- Emerging approaches to male contraception.Fertility and sterility · 2021Review
- Update on Novel Hormonal and Nonhormonal Male Contraceptive Development.The Journal of clinical endocrinology and metabolism · 2021Review
- Update on male hormonal contraception.Therapeutic advances in endocrinology and metabolism · 2019Review
- The future of male contraception: a fertile ground.Translational andrology and urology · 2018Review
- Male hormonal contraception: hope and promise.The lancet. Diabetes & endocrinology · 2017Review
- Pipeline for contraceptive development.Fertility and sterility · 2016Review
- Hormone-Based Treatments in Subfertile Males.Current urology reports · 2016Review
- Male hormonal contraception: looking back and moving forward.Andrology · 2016Review
- Advances in male hormonal contraception.The Indian journal of medical research · 2014Review
- Male Hormonal Contraception: Where Are We Now?Current obstetrics and gynecology reportsReview
- Would male hormonal contraceptives affect cardiovascular risk?Asian journal of andrologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 1 country.
Funding
Abstract
Development of a male hormonal contraceptive has been challenging ascribable to the failure to adequately suppress spermatogenesis in 5-10% of men. Methods to identify incomplete suppressors early in treatment might identify men most responsive to male hormonal contraceptives. We hypothesized that serum hormone and gonadotropin concentrations after 4 weeks of transdermal treatment with testosterone and Nestorone in a contraceptive trial would be associated with suppression of sperm concentrations to <1 million/mL after 24 weeks. Indeed, luteinizing hormone or follicle-stimulating hormone concentrations greater than 1 IU/L after 4 weeks of transdermal testosterone/nestorone treatment were 97% sensitive for predicting failure to suppress spermatogenesis after 24 weeks of treatment. Serum nestorone concentrations were significantly associated with suppression, but serum testosterone concentrations were not. Early suppression of gonadotropins is associated with, but does not ensure, adequate suppression of spermatogenesis. This information may allow for rapid identification of non-responders in male hormonal contraceptive trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.